Alicia Lundby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alicia Lundby has a total of 688 co-authors. Here are the top co-authors by number of shared publications:
- Jesper Velgaard Olsen
Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
14 shared publications - Søren-Peter Olesen
Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark
7 shared publications Estefania Torres Vega
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, Denmark
5 shared publications- John Francis Mulvey
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5 shared publications - Jonathan S. Achter
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5 shared publications - Kirstine Calloe
Department of Veterinary and Animal Sciences University of Copenhagen Frederiksberg Denmark
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1250-1270
Temporal proteomics maps concealed-stage remodeling and reveals early mitochondrial alteration as an intervention target in a model of PKP2-arrhythmogenic cardiomyopathy
- 29 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1250-1270
Open AccessTemporal proteomics maps concealed-stage remodeling and reveals early mitochondrial alteration as an intervention target in a model of PKP2-arrhythmogenic cardiomyopathy
- 25 September 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (10) , 908-910
A failing heart is a failing heart — until proteomics looks beyond etiology
- 25 September 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (10) , 908-910
A failing heart is a failing heart — until proteomics looks beyond etiology
- Open Access
- 9 July 2026
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 217, 189-199
Ligand-resolved in vivo phosphoproteomics of the adult heart maps ErbB signaling by EGF and NRG1β
- 9 July 2026
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 217, 189-199
Open AccessLigand-resolved in vivo phosphoproteomics of the adult heart maps ErbB signaling by EGF and NRG1β
- Open Access
ERBB4 deficiency promotes atrial myopathy underlying the atrial fibrillation substrate
Background: Atrial fibrillation (AF) is a leading cause of stroke, cardiovascular morbidity, and mortality. Atrial myopathy, characterized by progressive metabolic, electrical, and structural changes, creates the arrhythmogenic substrate that drives AF. Defining the key drivers of atrial myopathic processes is essential for targeted therapies that can mitigate AF progression. Here we explore how reduced ERBB4 expression contributes to the development of left atrial myopathy. Methods: We analyzed the Cleveland Clinic Biobank to compare left atrial ERBB4 levels in patients grouped by AF diagnosis. To investigate the impact of reduced ERBB4 levels on atrial tissue substrate, we created mouse models of cardiac-specific Erbb4 deficiency using Mlc2a (myosin light chain 2a)-Cre. Comprehensive physiological assessments were performed. Transcriptomic analyses of the left atrium were performed in an Erbb4 haploinsufficient mouse model and compared with human atrial datasets. Molecular validation of key dysregulated pathways was performed. Results: We found that left atrial ERBB4 levels are reduced in patients with AF. Adult cardiomyocyte-specific Erbb4 heterozygous ( Erbb4 fl/+ ;Mlc2a-Cre) mice exhibited prolonged P-wave duration in the absence of ventricular dysfunction. Left atrial transcriptomic analysis in Erbb4 haploinsufficient mice showed upregulation of pathways related to fibrosis, apoptosis, and coagulation, and downregulation of pathways related to fatty acid metabolism and mitochondrial function, mirroring changes observed in pressure overload mouse models. A cross-species transcriptomic comparison revealed significant overlap between ERBB4 -correlated gene expression and functional pathways in adult human atria and mice with Erbb4 haploinsufficiency. Validating the transcriptomic data, protein and functional assays demonstrated increased fibrosis, apoptosis, and oxidative stress in the mutant left atrial tissue. Conclusion: Left atrial ERBB4 levels are reduced in AF patients. A mouse model of Erbb4 deficiency and human atrial transcriptomic analyses highlight a role for ERBB4 in supporting normal atrial metabolism while protecting against inflammation, apoptosis, and fibrosis.
Open AccessERBB4 deficiency promotes atrial myopathy underlying the atrial fibrillation substrate
Background: Atrial fibrillation (AF) is a leading cause of stroke, cardiovascular morbidity, and mortality. Atrial myopathy, characterized by progressive metabolic, electrical, and structural changes, creates the arrhythmogenic substrate that drives AF. Defining the key drivers of atrial myopathic processes is essential for targeted therapies that can mitigate AF progression. Here we explore how reduced ERBB4 expression contributes to the development of left atrial myopathy. Methods: We analyzed the Cleveland Clinic Biobank to compare left atrial ERBB4 levels in patients grouped by AF diagnosis. To investigate the impact of reduced ERBB4 levels on atrial tissue substrate, we created mouse models of cardiac-specific Erbb4 deficiency using Mlc2a (myosin light chain 2a)-Cre. Comprehensive physiological assessments were performed. Transcriptomic analyses of the left atrium were performed in an Erbb4 haploinsufficient mouse model and compared with human atrial datasets. Molecular validation of key dysregulated pathways was performed. Results: We found that left atrial ERBB4 levels are reduced in patients with AF. Adult cardiomyocyte-specific Erbb4 heterozygous ( Erbb4 fl/+ ;Mlc2a-Cre) mice exhibited prolonged P-wave duration in the absence of ventricular dysfunction. Left atrial transcriptomic analysis in Erbb4 haploinsufficient mice showed upregulation of pathways related to fibrosis, apoptosis, and coagulation, and downregulation of pathways related to fatty acid metabolism and mitochondrial function, mirroring changes observed in pressure overload mouse models. A cross-species transcriptomic comparison revealed significant overlap between ERBB4 -correlated gene expression and functional pathways in adult human atria and mice with Erbb4 haploinsufficiency. Validating the transcriptomic data, protein and functional assays demonstrated increased fibrosis, apoptosis, and oxidative stress in the mutant left atrial tissue. Conclusion: Left atrial ERBB4 levels are reduced in AF patients. A mouse model of Erbb4 deficiency and human atrial transcriptomic analyses highlight a role for ERBB4 in supporting normal atrial metabolism while protecting against inflammation, apoptosis, and fibrosis.
- 25 May 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (6) , 526-540
Consensus statement on mass spectrometry-based proteomic analysis of cardiac tissue
Mass spectrometry-based cardiac proteomics provides direct molecular insight into cardiac physiology and disease. While plasma proteomics has advanced biomarker discovery, the analysis of cardiac tissue is essential for mechanistic understanding and therapeutic target identification; however, proteomic investigation of cardiac tissue faces unique challenges, including limited sample availability, regional heterogeneity, variability in collection and processing, and inconsistent reporting practices that hinder reproducibility and data integration. Here, we provide a practical framework for designing and conducting mass spectrometry-based proteomic studies of cardiac tissue and primary cardiac cells. We outline best practices and key considerations for sample handling, experimental design, data acquisition, quality control and statistical analysis. This guideline aims to support cardiac researchers in generating robust and reproducible proteomics datasets that advance our understanding of cardiac biology in both physiological and pathological contexts.
- 25 May 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (6) , 526-540
Consensus statement on mass spectrometry-based proteomic analysis of cardiac tissue
Mass spectrometry-based cardiac proteomics provides direct molecular insight into cardiac physiology and disease. While plasma proteomics has advanced biomarker discovery, the analysis of cardiac tissue is essential for mechanistic understanding and therapeutic target identification; however, proteomic investigation of cardiac tissue faces unique challenges, including limited sample availability, regional heterogeneity, variability in collection and processing, and inconsistent reporting practices that hinder reproducibility and data integration. Here, we provide a practical framework for designing and conducting mass spectrometry-based proteomic studies of cardiac tissue and primary cardiac cells. We outline best practices and key considerations for sample handling, experimental design, data acquisition, quality control and statistical analysis. This guideline aims to support cardiac researchers in generating robust and reproducible proteomics datasets that advance our understanding of cardiac biology in both physiological and pathological contexts.
- Open Access
- 14 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (2) , 101510
An Unbiased Molecular Characterization of Peripartum Cardiomyopathy Hearts Identifies Mast Cell Chymase as a New Diagnostic Candidate
- 14 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (2) , 101510
Open AccessAn Unbiased Molecular Characterization of Peripartum Cardiomyopathy Hearts Identifies Mast Cell Chymase as a New Diagnostic Candidate
- Open Access
- 7 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 6 (1)
Covariate balanced allocation of samples to batches to mitigate the impacts of technical variability
Performing assays on large numbers of samples requires their analysis in distinct batches, which commonly affects the measurements made in a systematic way. Analytical approaches can correct for such batch effects, however for this to be possible the batch should not be confounded with either the independent variable or any covariates relevant to the analysis. Thus, how samples are distributed across batches influences subsequent analytic conclusions. We present SampleAllocateR, an open source tool that employs optimisation methods from machine learning to optimally allocate a preselected set of samples to experimental batches in a way that statistically balances specified covariates between batches. This will result in better statistical estimates of the effect of not only the technical batch effects but also the other specified covariates upon the results of the experiment.
- 7 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 6 (1)
Open AccessCovariate balanced allocation of samples to batches to mitigate the impacts of technical variability
Performing assays on large numbers of samples requires their analysis in distinct batches, which commonly affects the measurements made in a systematic way. Analytical approaches can correct for such batch effects, however for this to be possible the batch should not be confounded with either the independent variable or any covariates relevant to the analysis. Thus, how samples are distributed across batches influences subsequent analytic conclusions. We present SampleAllocateR, an open source tool that employs optimisation methods from machine learning to optimally allocate a preselected set of samples to experimental batches in a way that statistically balances specified covariates between batches. This will result in better statistical estimates of the effect of not only the technical batch effects but also the other specified covariates upon the results of the experiment.
- Open Access
- 26 September 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (10) , 1-15
Quantitative proteomics of formalin-fixed, paraffin-embedded cardiac specimens uncovers protein signatures of specialized regions and patient groups
Proteomic technologies have advanced our understanding of disease mechanisms, patient stratification and targeted therapies. However, applying cardiac proteomics in translational research requires overcoming the barrier of tissue accessibility. Formalin-fixed, paraffin-embedded (FFPE) heart tissue, widely preserved in pathology collections, remains a largely untapped resource. Here we demonstrate that proteomic profiles are well preserved in FFPE human heart specimens and compatible with high-resolution, quantitative analysis. Quantifying approximately 4,000 proteins per sample, we show this approach effectively distinguishes disease states and subanatomical regions, revealing distinct underlying protein signatures. Specifically, the human sinoatrial node exhibited enrichment of collagen VI and G protein-coupled receptor signaling. Myocardial biopsies from patients with arrhythmogenic cardiomyopathy were characterized by fibrosis and metabolic/cytoskeletal derangements, clearly separating them from donor heart biopsies. This study establishes FFPE heart tissue as a robust resource for cardiac proteomics, enabling retrospective molecular profiling at scale and unlocking archived specimens for disease discovery and precision cardiology.
- 26 September 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (10) , 1-15
Open AccessQuantitative proteomics of formalin-fixed, paraffin-embedded cardiac specimens uncovers protein signatures of specialized regions and patient groups
Proteomic technologies have advanced our understanding of disease mechanisms, patient stratification and targeted therapies. However, applying cardiac proteomics in translational research requires overcoming the barrier of tissue accessibility. Formalin-fixed, paraffin-embedded (FFPE) heart tissue, widely preserved in pathology collections, remains a largely untapped resource. Here we demonstrate that proteomic profiles are well preserved in FFPE human heart specimens and compatible with high-resolution, quantitative analysis. Quantifying approximately 4,000 proteins per sample, we show this approach effectively distinguishes disease states and subanatomical regions, revealing distinct underlying protein signatures. Specifically, the human sinoatrial node exhibited enrichment of collagen VI and G protein-coupled receptor signaling. Myocardial biopsies from patients with arrhythmogenic cardiomyopathy were characterized by fibrosis and metabolic/cytoskeletal derangements, clearly separating them from donor heart biopsies. This study establishes FFPE heart tissue as a robust resource for cardiac proteomics, enabling retrospective molecular profiling at scale and unlocking archived specimens for disease discovery and precision cardiology.
- Open Access
Covariate balanced allocation of samples to batches to mitigate the impacts of technical variability
Performing assays on large numbers of samples requires their analysis in distinct batches, which commonly affects the measurements made in a systematic way. Analytical approaches can correct for such batch effects, however for this to be possible the batch should not be confounded with either the independent variable or any covariates relevant to the analysis. Thus, how samples are distributed across batches influences subsequent analytic conclusions. We present SampleAllocateR , an open source tool that employs optimisation methods from machine learning to optimally allocate a preselected set of samples to experimental batches in a way that statistically balances specified covariates between batches. This results in better statistical estimates of the effect of not only the technical batch effects but also the other specified covariates upon the results of the experiment.
Open AccessCovariate balanced allocation of samples to batches to mitigate the impacts of technical variability
Performing assays on large numbers of samples requires their analysis in distinct batches, which commonly affects the measurements made in a systematic way. Analytical approaches can correct for such batch effects, however for this to be possible the batch should not be confounded with either the independent variable or any covariates relevant to the analysis. Thus, how samples are distributed across batches influences subsequent analytic conclusions. We present SampleAllocateR , an open source tool that employs optimisation methods from machine learning to optimally allocate a preselected set of samples to experimental batches in a way that statistically balances specified covariates between batches. This results in better statistical estimates of the effect of not only the technical batch effects but also the other specified covariates upon the results of the experiment.
- Open Access
- 21 March 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-10
Integrating -Omic Technologies across Modality, Space, and Time to Decipher Remodeling in Cardiac Disease
Purpose of Review Despite significant efforts to understand pathophysiological processes underlying cardiac diseases, the molecular causes for the most part remain unresolved. Rapid advancements in -omics technologies, and their application in cardiac research, offer new insight into cardiac remodeling in disease states. This review aims to provide an accessible overview of recent advances in omics approaches for studying cardiac remodeling, catering to readers without extensive prior expertise. Recent Findings We provide a methodologically focused overview of current methods for performing transcriptomics and proteomics, including their extensions for single-cell and spatial measurements. We discuss approaches to integrate data across modalities, resolutions and time. Key recent applications within the cardiac field are highlighted. Summary Each -omics modality can provide insight, yet each existing experimental method has technical or conceptual limitations. Integrating data across multiple modalities can leverage strengths and mitigate weaknesses, ultimately enhancing our understanding of cardiac pathophysiology.
- 21 March 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-10
Open AccessIntegrating -Omic Technologies across Modality, Space, and Time to Decipher Remodeling in Cardiac Disease
Purpose of Review Despite significant efforts to understand pathophysiological processes underlying cardiac diseases, the molecular causes for the most part remain unresolved. Rapid advancements in -omics technologies, and their application in cardiac research, offer new insight into cardiac remodeling in disease states. This review aims to provide an accessible overview of recent advances in omics approaches for studying cardiac remodeling, catering to readers without extensive prior expertise. Recent Findings We provide a methodologically focused overview of current methods for performing transcriptomics and proteomics, including their extensions for single-cell and spatial measurements. We discuss approaches to integrate data across modalities, resolutions and time. Key recent applications within the cardiac field are highlighted. Summary Each -omics modality can provide insight, yet each existing experimental method has technical or conceptual limitations. Integrating data across multiple modalities can leverage strengths and mitigate weaknesses, ultimately enhancing our understanding of cardiac pathophysiology.